According to SciTechDaily, research published on December 22, 2025, in Cell Reports Medicine is challenging a core assumption about Alzheimer’s disease. Scientists from University Hospitals, Case Western Reserve University, and the Cleveland VA, led by Dr. Kalyani Chaubey and senior author Dr. Andrew A. Pieper, found that a severe drop in a cellular energy molecule called NAD is a key driver of the disease. In two different mouse models with advanced Alzheimer’s-like damage, restoring NAD balance with a drug called P7C3-A20 allowed the brain to repair itself, leading to a complete recovery of cognitive function. The mice even showed normalized levels of a key human Alzheimer’s biomarker, phosphorylated tau 217. The researchers are now pushing to commercialize the approach through a company called Glengary Brain Health and design human clinical trials.
A stunning result that defies dogma
Look, the history of Alzheimer’s research is littered with heartbreaking failures and “breakthroughs” that went nowhere. The dominant thinking for over a hundred years has been simple: once you lose brain function to this disease, it’s gone for good. All our efforts have been about prevention or, at best, slowing the grim march of decline. So when a study comes out claiming not just prevention, but full reversal of cognitive function in animals with advanced disease, you have to sit up and take notice. That’s exactly what this paper claims.
Here’s the thing that makes this different from a lot of mouse-model hype. They didn’t just use one genetic strain. They showed this recovery in two completely different mouse models—one driven by amyloid mutations, another by a tau mutation. Seeing the same dramatic effect in two different pathways is a big deal. It suggests they might be tapping into a fundamental mechanism, the brain’s energy crisis, rather than just patching one specific problem.
The catch? It’s not a supplement
Now, before anyone runs out to buy NAD booster supplements, pump the brakes. Dr. Pieper is very clear about this. The drug they used, P7C3-A20, isn’t just flooding the brain with NAD. It works by helping brain cells maintain a healthy balance of NAD during extreme stress. Basically, it’s a regulator, not a blunt force tool. And that’s critical, because slamming cells with too much NAD can apparently promote cancer, which is the last thing you want.
This is a crucial distinction that often gets lost in translation. The popular “biohacker” market is already full of NAD precursors like NMN and NR. But this research implies that indiscriminately boosting levels might be dangerous and is definitely not the same as the targeted, balance-restoring approach they’re studying. It’s a pharmaceutical strategy, not a wellness supplement.
The long road from mice to medicine
So, is this the cure we’ve been waiting for? Let’s be real. The graveyard of Alzheimer’s treatments is vast, and it’s built on the bones of promising animal studies that utterly failed in humans. Remember all the drugs that cleared amyloid plaques in mice but did nothing for human cognition? We’ve been here before.
The jump from a genetically engineered mouse living in a controlled lab to a 75-year-old human with a lifetime of complex biology and other health issues is astronomically huge. The brain damage in these mice is induced by specific mutations, but human Alzheimer’s is messier, with more variables. Will restoring energy balance be enough to untangle decades of degeneration? We simply don’t know.
A new direction for hope
Despite the necessary skepticism, this is genuinely exciting. Why? Because it fundamentally changes the question. For decades, the question has been “How do we stop it?” This research asks, “What if we can fix it?” That’s a seismic shift in mindset. Dr. Pieper’s statement that “the damaged brain can, under some conditions, repair itself and regain function” is a message of hope the Alzheimer’s field desperately needs.
The next steps are clear, and the team knows it: careful human trials. The fact that they’ve identified a potential biomarker (p-tau 217) that normalized in the mice is a huge help for designing those trials. You need a way to measure if the drug is doing anything in people before waiting years for cognitive results. They’re moving forward with commercialization, which is how this stuff actually gets to patients. It’s a long, expensive, and risky road. But for the first time in a long time, it’s a road that points toward recovery, not just managed decline.
